Genitourinary Cancers

Latest News

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.
CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer

June 3rd 2025

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of prior immunotherapy or tyrosine kinase inhibitor use.
Second-Line Cabozantinib Regimens Exhibit Efficacy in Advanced RCC

June 2nd 2025

Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.
ODAC Votes 8-to-0 Against First-Line Talazoparib/Enzalutamide in mCRPC

May 21st 2025

Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.
FDA Approves Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma

May 14th 2025

Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.
Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC

May 9th 2025